Autolomous has been included in Synthace‘s review of emerging tech for Cell & Gene Therapy manufacturing, under the ‘Software: Supply Chain and Manufacturing Data Management’ category.

See their full article for the complete list. Extract below:

“Cell and gene therapies are an emerging class of living therapeutics that have curative potential. The complexity of these therapies introduces system wide challenges which software and hardware companies seek to address. Herein we profile emerging frontier technology companies in this space.

Compared to a traditional biologic such as an antibody, CGT manufacturing is complex, labour intensive and expensive. The products also often have a constrained shelf life so tracking and securing the vein to vein supply chain becomes a challenge that has to be addressed. These factors are compounded by often smaller patient populations to produce therapies that, whilst curative, are prohibitively expensive for first or second-line usage.

As the field rapidly develops, techniques such as genome engineering, machine and deep learning for capsid engineering or neoantigen discovery, and single-cell analytics are also being used to create increasingly more precisely targeted therapies.

In response to the incredible biological promise and the challenges brought about by these living medicines, several emerging technology companies are developing software, data science and hardware solutions that seek to address the challenges associated with their discovery, manufacturing and supply. The end goal is to make ‘better’ therapies available to a wider patient population at a lower price.”